Table 2 Treatment outcomes in patients with uncomplicated Plasmodium falciparum and P. vivax infections treated with AL and DHA/PPQ for P. falciparum, and CQ and DHA/PPQ for P. vivax, Ethiopia, 2017

Late clinical failure

4

0

4

0

Late parasitological failure

2

0

18

0

Day of failure, 19–21

1

0

1

0

Day of failure, 22–28

1

0

2

0

Day of failure, 29–35

2

0

10

0

Day of failure, 36–42

2

0

9

0

Adequate clinical and parasitological response (% [95%CI])—day 28

99

(98% [93–100%])

68

(100% [95–100])

129

(98 [94–100%])

49

(100 [93–100%])

Kaplan–Meier estimate, uncorrected (95% CI)—day 28

98% (95–100%)

100%

98% (95–100%)

100%

Adequate clinical and parasitological response (%[95%CI])—day 42

–

68

(100% [95–100%])

–

49

(100% [93–100%])

Kaplan–Meier estimate, uncorrected (95% CI)—day 42

–

100%

–

100%

PCR-correction^a

 Recrudescence

0

0

2

0

 Reinfection

2

0

0

0

 PCR-correction not available

0

0

1

0

 Adequate clinical and parasitological response, PCR-corrected (% [95%CI])—day 28

99

(100% [96–100%])

–

129

(98% [95–100%]

–

 Kaplan–Meier estimate, PCR-corrected (95% CI)—day 28

100%

–

99%

(96–100%)

–